X0508 4 2026-03-02 0001815442 Kymera Therapeutics, Inc. KYMR 0001388406 Chadwick Jeremy G C/O KYMERA THERAPEUTICS, INC. 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 false true false false Chief Operating Officer false Common Stock 2026-03-02 4 A false 12575 0 A 79768 D Common Stock 2026-03-02 4 S false 549 87.7509 D 79219 D Common Stock 2026-03-02 4 S false 383 88.5004 D 78836 D Common Stock 2026-03-02 4 S false 1107 89.6574 D 77729 D Common Stock 2026-03-04 4 S false 394 83.9965 D 77335 D Common Stock 2026-03-04 4 S false 2017 85.0364 D 75318 D Common Stock 2026-03-04 4 S false 1150 85.7807 D 74168 D Common Stock 2026-03-04 4 S false 358 86.6247 D 73810 D Stock Option (Right to Buy) 90.1 2026-03-02 4 A false 25150 0 A 2036-03-01 Common Stock 25150 25150 D Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date. This number includes 773 shares and shares acquired under the Registrant's employee stock purchase plan. Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.11 to $88.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.11 to $89.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $90.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.36 to $84.3338, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.4475 to $85.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.45 to $86.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.48 to $86.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. /s/ Bruce Jacobs, as Attorney-in-Fact 2026-03-04